Bio-Techne Shareholders Face a $73-a-Share Crossroads — Did Merck KGaA's Bid Leave Money on the Table?

Bio-Techne shareholders convene virtually this morning at 9:00 a.m. Eastern for a decisive vote: accept Merck KGaA's $73-per-share, all-cash buyout, or reject it. The deal values the Minneapolis-based life sciences firm at roughly $11.3 billion , and its outcome will determine whether the company stays independent or becomes a wholly owned subsidiary of the German science-and-technology conglomerate. Here is what investors need to know.

• A Hefty Premium, but the Stock Was Already Beaten Down

The $73 offer represents a 36% premium to Bio-Techne's one-month average trading price and a roughly 24% premium to its closing price the day before the deal was announced . That sounds generous — until you consider context. Bio-Techne's stock had fallen nearly 50% over the prior five years , pressured by weak demand in China, cuts to U.S. research funding, and sluggish pharmaceutical spending. In other words, Merck is buying at a discount to where the company once traded, even as the deal pays a premium to recent prices.

• A Lawsuit Tried — and Failed — to Block Today's Vote

A shareholder suit filed September 9 in Minnesota state court alleged the company's proxy statement omitted material information and sought an injunction to halt today's vote . Bio-Techne called the claims "without merit" and said its disclosures "comply fully with all applicable law," though it voluntarily issued supplemental disclosures to defuse the challenge. The vote is proceeding as scheduled, suggesting the suit did not gain enough traction to delay matters.

• The Financials Show a Company Running Out of Growth Catalysts

Fourth-quarter fiscal 2026 revenue came in at $321.2 million, beating estimates, but grew only 1% year-over-year (3% on an organic basis), while adjusted earnings per share slipped to $0.52 from $0.53 . Benchmark reiterated a Hold rating . With growth stalling and analysts projecting quarterly EPS of just $0.46–$0.60 , the $73 cash-out offers certainty that the stock's standalone trajectory may not.

• Merck's Strategic Logic — and the Termination-Fee Safety Net

Merck's Life Science CEO called Bio-Techne's catalog of 6,000 proteins and 425,000 antibodies a "big, big plus" , signaling this is a scale play in reagents and diagnostics. Merck expects roughly €140 million in cost savings fully realized by year three . If the deal falls apart, Bio-Techne would owe a termination fee of approximately $230.5 million — a powerful incentive for the board to push the vote through.

Bottom line: Shareholders are trading a flatlining growth story for guaranteed cash. The premium is real, but so is the argument that patient investors in a cyclical recovery could have eventually done better.